256 related articles for article (PubMed ID: 10895085)
1. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
[TBL] [Abstract][Full Text] [Related]
2. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
3. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
[TBL] [Abstract][Full Text] [Related]
4. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
6. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
7. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
8. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
[TBL] [Abstract][Full Text] [Related]
11. Elevated urinary fibronectin levels after transurethral resection of bladder tumour: a possible role in patients failing therapy with bacillus Calmette-Guérin.
Laufer M; Kaver I; Sela B; Matzkin H
BJU Int; 1999 Sep; 84(4):428-32. PubMed ID: 10468755
[TBL] [Abstract][Full Text] [Related]
12. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
14. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
[TBL] [Abstract][Full Text] [Related]
16. Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guérin treatment for high-risk superficial bladder cancer.
Biers SM; Di Marco A; Mostafid AH
Int Urol Nephrol; 2007; 39(4):1039-41. PubMed ID: 17431810
[TBL] [Abstract][Full Text] [Related]
17. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
Witjes JA; vd Meijden AP; Doesburg W; Debruyne FM
Eur Urol; 1993; 23(3):366-70. PubMed ID: 8508889
[TBL] [Abstract][Full Text] [Related]
18. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
19. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
20. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
Karakiewicz PI; Benayoun S; Lewinshtein DJ; Chun FK; Shahrour K; Perrotte P
Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
